Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies Journal Article

Local Library Link: Find It @ Loyola

Authors: Zhai, Y.; Zhong, Z.; Zariffard, M.; Spear, G. T.; Qiao, L
Article Title: Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies
Abstract: Two conserved epitopes, located in the membrane-proximal external region (MPER) of the human immunodeficiency virus type 1 (HIV-1) gp41, are recognized by two HIV-1 broadly neutralizing antibodies 2F5 and 4E10, and are promising targets for vaccine design in efforts to elicit anti-HIV-1 broadly neutralizing antibodies. Since most HIV-1 infections initiate at mucosal surfaces, induction of mucosal neutralizing antibodies is necessary and of utmost importance to counteract HIV-1 infection. Here, we utilized a mucosal vaccine vector, bovine papillomavirus (BPV) virus-like particles (VLPs), as a platform to present HIV-1 neutralizing epitopes by inserting the extended 2F5 or 4E10 epitope or the MPER domain into D-E loop of BPV L1 respectively. The chimeric VLPs presenting MPER domain resembled the HIV-1 natural epitopes better than the chimeric VLPs presenting single epitopes. Oral immunization of mice with the chimeric VLPs displaying the 2F5 epitope or MPER domain elicited epitope-specific serum IgGs and mucosal secretory IgAs. The induced antibodies specifically recognized the native conformation of MPER in the context of HIV-1 envelope protein. The antibodies induced by chimeric VLPs presenting MPER domain are able to partially neutralize HIV-1 viruses from clade B and clade C.
Journal Title: Vaccine
Volume: 31
Issue: 46
ISSN: 1873-2518; 0264-410X
Publisher: Unknown  
Journal Place: Netherlands
Date Published: 2013
Start Page: 5422
End Page: 5429
Language: eng
DOI/URL:

10.1016/j.vaccine.2013.09.003
Notes: LR: 20141112; CI: Copyright (c) 2013; GR: DE019075/DE/NIDCR NIH HHS/United States; GR: R01 DE019075/DE/NIDCR NIH HHS/United States; JID: 8406899; 0 (AIDS Vaccines); 0 (Drug Carriers); 0 (Epitopes); 0 (HIV Antibodies); 0 (HIV Envelope Protein gp41); 0 (Immunoglobulin A, Secretory); 0 (Immunoglobulin G); 0 (Vaccines, Synthetic); 0 (Vaccines, Virus-Like Particle); 0 (gp41 protein, Human immunodeficiency virus 1); NIHMS524417; OID: NLM: NIHMS524417; OID: NLM: PMC3881962; OTO: NOTNLM; 2013/03/16 [received]; 2013/07/14 [revised]; 2013/09/06 [accepted]; 2013/09/19 [aheadofprint]; ppublish